IHCH-3064

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

IHCH-3064 

IHCH-3064 是一种靶向腺苷 A2A 受体和 HDAC 的双效化合物。IHCH-3064 有效结合到 A2AR (Ki=2.2 nM) ,且选择性抑制 HDAC1 (IC50=80.2 nM),在体外对肿瘤细胞具有良好的抗增殖活性。IHCH-3064 是一种肿瘤免疫治疗剂。

IHCH-3064

IHCH-3064 Chemical Structure

CAS No. : 2420562-65-6

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

IHCH-3064 is a dual-acting compounds targeting Adenosine A2A Receptor and HDAC. IHCH-3064 exhibits potent binding to A2AR (Ki=2.2 nM) and selective inhibition of HDAC1 (IC50=80.2 nM), with good antiproliferative activity against tumor cell lines in vitro. IHCH-3064 is a tumor immunotherapeutic agent[1].

分子量

479.49

Formula

C25H21N9O2

CAS 号

2420562-65-6

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Wenzhong Yan, et al. Structure-Based Design of Dual-Acting Compounds Targeting Adenosine A 2A Receptor and Histone Deacetylase as Novel Tumor Immunotherapeutic Agents. J Med Chem. 2021 Nov 25;64(22):16573-16597.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

IHCH-3064

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

IHCH-3064 

IHCH-3064 是一种靶向腺苷 A2A 受体和 HDAC 的双效化合物。IHCH-3064 有效结合到 A2AR (Ki=2.2 nM) ,且选择性抑制 HDAC1 (IC50=80.2 nM),在体外对肿瘤细胞具有良好的抗增殖活性。IHCH-3064 是一种肿瘤免疫治疗剂。

IHCH-3064

IHCH-3064 Chemical Structure

CAS No. : 2420562-65-6

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

IHCH-3064 is a dual-acting compounds targeting Adenosine A2A Receptor and HDAC. IHCH-3064 exhibits potent binding to A2AR (Ki=2.2 nM) and selective inhibition of HDAC1 (IC50=80.2 nM), with good antiproliferative activity against tumor cell lines in vitro. IHCH-3064 is a tumor immunotherapeutic agent[1].

分子量

479.49

Formula

C25H21N9O2

CAS 号

2420562-65-6

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Wenzhong Yan, et al. Structure-Based Design of Dual-Acting Compounds Targeting Adenosine A 2A Receptor and Histone Deacetylase as Novel Tumor Immunotherapeutic Agents. J Med Chem. 2021 Nov 25;64(22):16573-16597.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

IHCH-3064

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

IHCH-3064 

IHCH-3064 是一种靶向腺苷 A2A 受体和 HDAC 的双效化合物。IHCH-3064 有效结合到 A2AR (Ki=2.2 nM) ,且选择性抑制 HDAC1 (IC50=80.2 nM),在体外对肿瘤细胞具有良好的抗增殖活性。IHCH-3064 是一种肿瘤免疫治疗剂。

IHCH-3064

IHCH-3064 Chemical Structure

CAS No. : 2420562-65-6

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

IHCH-3064 is a dual-acting compounds targeting Adenosine A2A Receptor and HDAC. IHCH-3064 exhibits potent binding to A2AR (Ki=2.2 nM) and selective inhibition of HDAC1 (IC50=80.2 nM), with good antiproliferative activity against tumor cell lines in vitro. IHCH-3064 is a tumor immunotherapeutic agent[1].

分子量

479.49

Formula

C25H21N9O2

CAS 号

2420562-65-6

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Wenzhong Yan, et al. Structure-Based Design of Dual-Acting Compounds Targeting Adenosine A 2A Receptor and Histone Deacetylase as Novel Tumor Immunotherapeutic Agents. J Med Chem. 2021 Nov 25;64(22):16573-16597.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务